These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 19841449)

  • 1. ACP Journal Club. Quadrivalent HPV vaccine reduced risk for HPV infection and related disease in women 24 to 45 years of age.
    Granwehr BP
    Ann Intern Med; 2009 Oct; 151(8):JC4-12. PubMed ID: 19841449
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP journal club. Quadrivalent HPV vaccine prevented HPV infection and external genital lesions in boys and men 16 to 26 years of age.
    Bender BS
    Ann Intern Med; 2011 May; 154(10):JC5-10. PubMed ID: 21576528
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials.
    Paavonen J;
    Curr Med Res Opin; 2008 Jun; 24(6):1623-34. PubMed ID: 18435868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and incidence of HPV genital infection in women.
    Velicer C; Zhu X; Vuocolo S; Liaw KL; Saah A
    Sex Transm Dis; 2009 Nov; 36(11):696-703. PubMed ID: 19652630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
    Dee A; Howell F
    Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
    Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
    Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
    Villa LL
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics.
    Pomfret TC; Gagnon JM; Gilchrist AT
    J Clin Pharm Ther; 2011 Feb; 36(1):1-9. PubMed ID: 21198715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
    Mahoney MC
    J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACP Journal Club. HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women.
    Budenholzer B
    Ann Intern Med; 2012 Jul; 157(2):JC2-6, JC2-7. PubMed ID: 22801705
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quadrivalent HPV 6/11/16/18 vaccine].
    Kjaer SK; Andersen ES; Djursing H; Hansen T; Jørgensen JJ; Nilas L; Ottesen BS; Petersen LK; Thomsen SG; Toftager-Larsen K
    Ugeskr Laeger; 2007 Nov; 169(46):3971-4. PubMed ID: 18078651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
    Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
    J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prophylactic role for the human papillomavirus quadrivalent vaccine in males.
    Yancey AM; Pitlick JM; Forinash AB
    Ann Pharmacother; 2010; 44(7-8):1314-8. PubMed ID: 20501891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine.
    Giuliano AR; Lazcano-Ponce E; Villa L; Nolan T; Marchant C; Radley D; Golm G; McCarroll K; Yu J; Esser MT; Vuocolo SC; Barr E
    J Infect Dis; 2007 Oct; 196(8):1153-62. PubMed ID: 17955433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine.
    Garland SM; Steben M; Sings HL; James M; Lu S; Railkar R; Barr E; Haupt RM; Joura EA
    J Infect Dis; 2009 Mar; 199(6):805-14. PubMed ID: 19199546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits of vaccinating young adult women with a prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine.
    Monsonego J; Cortes J; Greppe C; Hampl M; Joura E; Singer A
    Vaccine; 2010 Nov; 28(51):8065-72. PubMed ID: 20971114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent human papillomavirus vaccine.
    Barr E; Tamms G
    Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.